Work

Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment.

Year: 2007

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v110.11.250.250

Authors: Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Pamela Becker, Adam Boruchov, David Bowen, Richard Larson, Roger Lyons, Petra Muus, Jamile Shammo, Michael Ehrman, Kuolung Hu, Janet Nichol

Institutions: The University of Texas MD Anderson Cancer Center, Hôpital Avicenne, Cleveland Clinic, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, Leeds Teaching Hospitals NHS Trust, University of Chicago, Radboud University Medical Center, Rush University Medical Center, Amgen (United States)

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591949526

FWCI: 6.768

Cites:

Cited by: 42

Related to: 10